Table 1 Associations of ANGPTL4 loss-of- function variants and type 2 diabetes

From: Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes

 

ANGPTL4 LoF carriers

Total

Frequency

Study

Cases

Controls

Cases

Controls

Cases

Controls

DiscovEHR

22

85

12,969

36,217

0.0008

0.0012

DiscovEHR 30K replication

5

47

3,456

22,372

0.0007

0.0011

UPenn

3

13

734

4,066

0.0020

0.0016

Duke

2

10

1,630

4,903

0.0006

0.0010

TAICHI

0

3

4,392

4,699

0.0000

0.0003

DHS-EA

0

5

104

1,255

0.0000

0.0020

DHS-AA

0

1

357

2,028

0.0000

0.0002

T2D-Genes/GoT2D/DIAGRAM

14

19

8,373

8,466

0.0008

0.0011

Total

46

183

32,015

84,006

0.0007

0.0011

  1. AA African American, CI confidence interval, Duke Duke CATHGEN cohort, EA European American, TD2-Genes/GoT2D/DIAGRAM combined analysis of T2D-GENES, GoT2D and DIAGRAM studies, pLoF predicted loss-of-function variant, Penn University of Pennsylvania Medicine Biobank, TAICHI TAIwan MetaboCHIp consortium
  2. The overall odds ratio for ANGPTL4 pLoFs and type 2 diabetes risk, using a two-sided exact conditional test, was 0.71 (95% CI 0.49–0.99, p = 0.041)
Back to article page